✨ Your Portfolio is fetched and updated from zerodha.
Market Cap
₹4,739 Cr.
P/E
35.04
About
Supriya Lifescience Limited is a leading Indian manufacturer and supplier of active pharmaceutical ingredients (APIs) specializing in research and development. They offer a range of niche APIs caterin… Read more
Supriya Lifescience Limited is a leading Indian manufacturer and supplier of active pharmaceut… Read more
Low
235
52W Range
High
675
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Custom financial statement
Edit rows
Forensics

7 Yes

Positive for this company

3 Neutral

Neutral for this company

6 No

Negative for this company

1 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Therapeutic Area Break-Up

Peer Comparison
FAQs on Supriya Lifescience Ltd. Business

Supriya Lifescience Limited is an Indian manufacturer and supplier of APIs, focusing on research and development. They offer a diverse range of niche APIs for different therapeutic segments and have a significant market presence globally.

Supriya Lifescience major competitors are AMI Organics, Aether Industries, Aarti Drugs, Morepen Laboratories, Aarti Pharmalabs, Solara Active Pharma, SMS Pharmaceuticals.
Market Cap of Supriya Lifescience is ₹5,076 Crs.
While the median market cap of its peers are ₹4,825 Crs.

Supriya Lifescience seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing
2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Investor Presentation Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Conference Call Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Sep Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Discussions & Analysis